Search Results for: dg11

Calprotectin Testing Goes Mobile With advances in technology and the ubiquitous use of mobile devices, a huge opportunity has arisen to change the way some healthcare services are provided. This is especially applicable to the management of chronic conditions. With most people owning a mobile device or tablet this becomes a convenient way for patients to

Dr. James Turvill, Consultant Gastroenterologist at York Teaching Hospital NHS Foundation Trust was one of the experts speaking at Alpha Laboratories Digestive Diseases Day in November 2017 where he discussed the application of calprotectin testing in clinical care. Since 2008 Dr. Turvill has developed a research interest in the use of biomarkers to facilitate in the

Introduction Calprotectin is a heterodimer of calcium-binding proteins which belongs to the S-100 protein family. It is released from neutrophils and monocytes during cellular activation (or death) at sites of active inflammation, and accounts for upto 60% of the cytosolic protein in the granules of these cells. It is a highly stable protein, resists enzymatic

Faecal calprotectin testing hit the news headlines late last year following publication of the NICE diagnostic guidelines: ‘Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel’ (DG11). Measurement of faecal calprotectin is considered to provide a reliable indicator of gastrointestinal (GI) tract inflammation and numerous studies show that, while faecal calprotectin concentrations are significantly

In October 2013 NICE produced guidance (DG11) recommending the use of faecal calprotectin testing to help doctors distinguish between inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, and non-inflammatory bowel diseases, such as irritable bowel syndrome. You can read more about the NICE guidelines here. The Health Technologies Adoption Programme (HTAP) are now

Calprotectin is a protein biomarker that is present in the faeces when intestinal inflammation occurs. Faecal calprotectin testing is helping to improve patient care and save money for the NHS. It prevents the need for unnecessary endoscopy procedures on many patients by screening out those with Irritable Bowel Syndrome (IBS). The symptoms of functional disorders such

About Calprotectin

Faecal Calprotectin is a new biomarker which is helping to save money for the NHS by preventing unnecessary procedures on patients by screening out patients with IBS who do not require endoscopies.

The symptoms of functional disorders such as Irritable Bowel Syndrome (IBS) and organic inflammatory intestinal disease (IBD) can be very similar in presentation but are two very different medical conditions.